GERN - Geron Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.6900
-0.1400 (-7.65%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.8300
Open1.8200
Bid1.7000 x 1400
Ask1.7500 x 1000
Day's Range1.6800 - 1.8300
52 Week Range0.9500 - 6.9900
Volume4,432,249
Avg. Volume3,257,293
Market Cap315.004M
Beta (3Y Monthly)2.61
PE Ratio (TTM)N/A
EPS (TTM)-0.1530
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.63
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 78,400 shares of Geron common stock as inducements to two newly-hired employees in connection with commencement of employment with the Company. The stock options were granted on March 20, 2019 at an exercise price of $1.77 per share, which is equal to the closing price of Geron common stock on the date of grant. Each stock option granted has a 10-year term and vests over four years, with 12.5% of the shares underlying the option vesting on the six-month anniversary of commencement of employment and the remaining shares vesting over the following 42 months in equal installments of whole shares, subject to continued employment with Geron through the applicable vesting dates.

  • 3 Penny Stocks That Could Make You Rich -- or Regretful
    Motley Fool9 days ago

    3 Penny Stocks That Could Make You Rich -- or Regretful

    These three penny stocks have enormous upside potential, but they each come with a hefty dose of risk.

  • Do Options Traders Know Something About Geron (GERN) Stock We Don't?
    Zacks9 days ago

    Do Options Traders Know Something About Geron (GERN) Stock We Don't?

    Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

  • Thomson Reuters StreetEvents10 days ago

    Edited Transcript of GERN earnings conference call or presentation 7-Mar-19 9:30pm GMT

    Q4 2018 Geron Corp Earnings Call

  • 3 Small-Cap Stocks With Big-Cap Potential
    Motley Fool12 days ago

    3 Small-Cap Stocks With Big-Cap Potential

    Warning: Small-cap stocks are risky, but the risk might be worth taking sometimes. Like with these three companies.

  • Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up
    Zacks15 days ago

    Geron's (GERN) Q4 Loss In Line, Revenues Beat, Stock Up

    Geron (GERN) posts loss in line with the estimate in fourth-quarter 2018 but beats on revenues. Operating expenses increase on a year-over-year basis.

  • Geron Corportaion (GERN) Q4 2018Earnings Conference Call Transcript
    Motley Fool15 days ago

    Geron Corportaion (GERN) Q4 2018Earnings Conference Call Transcript

    GERN earnings call for the period ending December 31, 2018.

  • GlobeNewswire16 days ago

    Geron Corporation Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Events

    MENLO PARK, Calif., March 07, 2019 -- Geron Corporation (Nasdaq: GERN) today reported financial results for the fourth quarter and full year ended December 31, 2018 and recent.

  • Why Geron Skyrocketed 27% in February
    Motley Fool18 days ago

    Why Geron Skyrocketed 27% in February

    Investors are hopeful that this struggling biotech is about to get back on track.

  • The 3 Oldest Members of Biotech's Billion-Burned Club
    Motley Fool19 days ago

    The 3 Oldest Members of Biotech's Billion-Burned Club

    These biopharmaceutical startups have been losing their investors' money for decades.

  • GlobeNewswire23 days ago

    Geron to Announce Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019

    Geron Corporation (GERN) today announced that it will release its fourth quarter and full year 2018 financial results after the market closes on Thursday, March 7, 2019 via press release, which will be available on the Company’s website at www.geron.com/investors. Geron will host a conference call to discuss the financial results as well as recent events at 4:30 p.m. ET the same day. Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

  • Could Geron Be a Millionaire-Maker Stock?
    Motley Fool28 days ago

    Could Geron Be a Millionaire-Maker Stock?

    Can this penny biotech stock make early-bird investors rich?

  • Why Geron Stock Briefly Spiked Today
    Motley Foollast month

    Why Geron Stock Briefly Spiked Today

    This morning's move followed an upgrade by BTIG.

  • GlobeNewswirelast month

    Analysis: Positioning to Benefit within National Oilwell Varco, Centene, Paylocity Holding, NorthStar Realty Europe, Geron, and NACCO Industries — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, Feb. 08, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Are Options Traders Betting on a Big Move in Geron (GERN) Stock?
    Zackslast month

    Are Options Traders Betting on a Big Move in Geron (GERN) Stock?

    Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.

  • ACCESSWIRE2 months ago

    Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / February 5, 2019 / Some consider the small-cap and mid-cap - ''smid-cap'' - zone with market caps of $5 billion or less, a bit risky. They aren't wrong. However, if you can ...

  • How Much is Geron Corporation’s (NASDAQ:GERN) CEO Getting Paid?
    Simply Wall St.2 months ago

    How Much is Geron Corporation’s (NASDAQ:GERN) CEO Getting Paid?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In 2011 Chip Scarlett was appointed CEO Read More...

  • GlobeNewswire2 months ago

    Geron Announces Expansion of Leadership Team with Appointment of Chief Medical Officer

    Geron Corporation (GERN) today announced an expansion of its leadership team with the appointment of a new chief medical officer to support the Company’s clinical drug development efforts in hematology-oncology. “As we transition to a late-stage development company, we are very pleased to welcome Dr. Aleksandra Rizo to Geron as Chief Medical Officer,” said John A. Scarlett, M.D., Chairman and Chief Executive Officer.

  • ACCESSWIRE2 months ago

    4 Biotech Stocks Making Moves On Thursday (1/31/19)

    Premier Health Group (OTC:PHGRF) (CSE:PHGI), SCYNEXIS Inc (SCYX), Geron Corporation (GERN), and Fortress Biotech Inc (FBIO) represent four biotech companies creating new treatment technologies aimed to ensure that patients get the therapies best suited to their needs. Premier Health Group (OTC:PHGRF) (CSE:PHGI) announced earlier this week that, further to its news release dated January 10, 2019, the Company has acquired all outstanding securities of Cloud Practice Inc. As a result of the acquisition, Cloud Practice's Founders, including CEO Jordan Visco, and entire support team, consisting of several software developers and sales staff, will join and work alongside the Premier Health team to offer tools and resources providing for better efficiency on a day-to-day basis for both physicians and customers.

  • ACCESSWIRE2 months ago

    Biotech Stocks on the Rise

    HENDERSON, NV / ACCESSWIRE / January 31, 2019 / With the IBB getting set to cap off its most bullish month in a while, the biotech industry could be in store for a major renaissance in 2019. Below are ...

  • ACCESSWIRE2 months ago

    Best Ways to Play Biotech Rally

    HENDERSON, NV / ACCESSWIRE / January 23, 2019 / The market reached a level toward the end of last year where investors and analysts were throwing the "R" word (recession) around. The cause of ...

  • GlobeNewswire2 months ago

    Geron Appoints Vice President, Pharmacovigilance and Drug Safety

    Geron Corporation (GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk myelodysplastic syndromes by mid-year 2019. Israel Gutierrez, M.D., has joined the Company as Vice President, Pharmacovigilance and Drug Safety, as of January 16, 2019. Dr. Gutierrez will lead and direct the oversight of clinical drug safety risk management and compliance at Geron and will be responsible for product safety-related recommendations and decisions.

  • Why Geron Stock Dropped 44% in 2018
    Motley Fool2 months ago

    Why Geron Stock Dropped 44% in 2018

    Johnson & Johnson's decision to hand back imetelstat's rights caused Geron's share price to crumble last year.

  • GlobeNewswire3 months ago

    Geron Announces New Board Leadership Structure

    For personal reasons, effective December 26, 2018, Hoyoung Huh, M.D., Ph.D., has resigned from the Board, including his roles as Chairman of the Board and as a member of the Nominating and Corporate Governance Committee. Dr. Huh has served as Chairman of the Board since September 2011, and as a member of the Board since May 2010.

  • ACCESSWIRE3 months ago

    Biotech Breakout Candidates

    HENDERSON, NV / ACCESSWIRE / December 24, 2018 / It’s been a busy week for biotech, here are a few companies in the news you should start researching. Today we are highlighting: Delcath Systems, Inc. (DCTH), ...